{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T22:43:38Z","timestamp":1782341018264,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"European Commission\u2019s FP7 Framework Programme","award":["305983"],"award-info":[{"award-number":["305983"]}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Health Policy"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.healthpol.2018.11.015","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T18:41:12Z","timestamp":1543516872000},"page":"152-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Using a stated preference discrete choice experiment to assess societal value from the perspective of decision-makers in Europe. Does it work for rare diseases?"],"prefix":"10.1016","volume":"123","author":[{"given":"J.","family":"L\u00f3pez-Bastida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Ramos-Go\u00f1i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Aranda-Reneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Trapero-Bertran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kanavos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Rodriguez Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healthpol.2018.11.015_bib0005","series-title":"Rare diseases and orphan products. Accelerating research and development","author":"Institute of Medicine of the National Academies (IMNA)","year":"2010"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0010","series-title":"Improving access to orphan medicines for all affected EU citizens","author":"European Commission (EC)","year":"2004"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10198-016-0780-7","article-title":"Social\/economic costs and health-related quality of life in patients with rare diseases in Europe","volume":"17","author":"L\u00f3pez-Bastida","year":"2016","journal-title":"The European Journal of Health Economics"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0020","first-page":"183","article-title":"Orphan drug policies: implications for the United States, Canada, and developing countries","volume":"12","author":"Cheung","year":"2004","journal-title":"Health Law Journal"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0025","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2125.2006.02654.x","article-title":"Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products","volume":"62","author":"Dear","year":"2006","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1017\/S0266462307051550","article-title":"Assessing the economic challenges posed by orphan drugs","volume":"23","author":"Drummond","year":"2007","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0168-8510(99)00043-3","article-title":"Public views on health care rationing: a group discussion study","volume":"49","author":"Cookson","year":"1999","journal-title":"Health Policy"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0040","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hec.924","article-title":"QALY maximisation and people\u2019s preferences: a methodological review of the literature","volume":"14","author":"Dolan","year":"2005","journal-title":"Health Economy"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-6-42","article-title":"Pricing and reimbursement of orphan drugs: the need for more transparency","volume":"6","author":"Simoens","year":"2011","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13023-015-0269-y","article-title":"Principles for consistent value assessment and sustainable funding of orphan drugs in Europe","volume":"10","author":"Gutierrez","year":"2015","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0055","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jval.2013.10.002","article-title":"A pilot study of multicriteria decision analysis for valuing orphan medicines","volume":"16","author":"Sussex","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0060","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1750-1172-7-74","article-title":"Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?","volume":"7","author":"Hughes-Wilson","year":"2012","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40273-014-0235-x","article-title":"Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework","volume":"33","author":"Paulden","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0070","article-title":"Incorporating multiple criteria in HTA \u2013 methods and processes","author":"Devlin","year":"2011","journal-title":"London: Office of Health Economics"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0075","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s10198-013-0517-9","article-title":"A multi-criteria decision analysis perspective on the health economic evaluation of medical interventions","volume":"15","author":"Postmus","year":"2014","journal-title":"The European Journal of Health Economics"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0080","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jval.2012.06.015","article-title":"Multiple criteria decision analysis for health technology assessment","volume":"15","author":"Thokala","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0085","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.mehy.2015.06.024","article-title":"Is it the time to rethink clinical decision-making strategies? From a single clinical outcome evaluation to a Clinical Multi-criteria Decision Assessment (CMDA)","volume":"85","author":"Migliore","year":"2015","journal-title":"Medical Hypotheses"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0090","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/hec.1414","article-title":"Exploring the social value of health-care interventions: a stated preference discrete choice experiment","volume":"18","author":"Green","year":"2009","journal-title":"Health Economy"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0095","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40273-014-0170-x","article-title":"Discrete choice experiments in health economics: a review of the literature","volume":"32","author":"Clark","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0100","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/MLR.0000000000000178","article-title":"Multinational evidence of the applicability and robustness of discrete choice modeling for deriving EQ-5D-5L health-state values","volume":"52","author":"Krabbe","year":"2014","journal-title":"Medical Care"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0105","article-title":"Which attributes should include a Discrete Choice Experiment for rare diseases: a systematic literature review","author":"Trapero-Bertr\u00e1n","year":"2015","journal-title":"XXXV Jornadas de Economia de la Salud"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0110","series-title":"Frontriers in econometrics","article-title":"Conditional logit analysis of qualitative choice behavior","author":"McFadden","year":"1974"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0115","series-title":"Stata statistical software: release 14","author":"StataCorp","year":"2015"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0120","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/qjmed\/hci128","article-title":"Drugs for exceptionally rare diseases: do they deserve special status for funding?","volume":"98","author":"Hughes","year":"2005","journal-title":"QJM: Monthly Journal of the Association of Physicians"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0125","series-title":"NICE citizens council report: ultra orphan drugs","author":"NICE Citizens Council","year":"2004"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13023-016-0388-0","article-title":"Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs","volume":"11","author":"Kolasa","year":"2016","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0135","doi-asserted-by":"crossref","first-page":"A550","DOI":"10.1016\/j.jval.2015.09.1766","article-title":"Orphan drugs assessment in Germany: a comparison with other international HTA agencies","volume":"18","author":"Mycka","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0140","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s10198-016-0823-0","article-title":"Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries","volume":"18","author":"Nicod","year":"2017","journal-title":"The European Journal of Health Economics"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0145","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jval.2012.06.009","article-title":"An evaluation framework for funding drugs for rare diseases","volume":"15","author":"Winquist","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0150","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1017\/S1744133110000344","article-title":"A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study","volume":"6","author":"Mentzakis","year":"2011","journal-title":"Health Economics, Policy, and Law"},{"key":"10.1016\/j.healthpol.2018.11.015_bib0155","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13023-016-0444-9","article-title":"Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers","volume":"11","author":"Morel","year":"2016","journal-title":"Orphanet Journal of Rare Diseases"}],"container-title":["Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168851018306614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168851018306614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T08:14:39Z","timestamp":1717229679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168851018306614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0168851018306614"],"URL":"https:\/\/doi.org\/10.1016\/j.healthpol.2018.11.015","relation":{},"ISSN":["0168-8510"],"issn-type":[{"value":"0168-8510","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using a stated preference discrete choice experiment to assess societal value from the perspective of decision-makers in Europe. Does it work for rare diseases?","name":"articletitle","label":"Article Title"},{"value":"Health Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healthpol.2018.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}